SER

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

PRE 14A - Serina Therapeutics, Inc. (0001708599) (Filer)

– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads – HUNTSVILLE, AL, April 07, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Serina Therapeutics Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 5th LNP Formulation & Process Development Summit in Boston, MA. Entitled "Novel Lipid Nanoparticles Built

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported that the NYSE American LLC ("NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) or 1003(a)(ii) of the NYSE American Company Guide. "We are pleased that NYSE American has accepted our plan to regain compliance with its continued listing standards," said Steve Ledger, CEO of Serina. "We remain focused on executing the SER-252 clinical program and advancing our P

10-K/A - Serina Therapeutics, Inc. (0001708599) (Filer)

S-8 - Serina Therapeutics, Inc. (0001708599) (Filer)

- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead," said Steve Ledger, CEO of S

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

10-K - Serina Therapeutics, Inc. (0001708599) (Filer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST. A live webcast of the fireside chat style presentation will be accessible to registered attendees at this link. An archived replay will be available on-demand for 90 days following the event. About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned dru

8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price– - Financing includes 50% warrant coverage priced at $5 per share, representing a 273% premium to market, if exercised would raise up to an additional $33.3 million, extending runway into 2H 2027 - - Proceeds to support ongoing single-ascending dose (SAD) registrational study arm under 505(b)(2) NDA pathway – HUNTSVILLE, AL, March 18, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina

- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient development strategy leveraging POZ Platform™ - HUNTSVILLE, AL, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, today announced that it has dosed the first patient in its Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson's disease. The Phase 1

- First patient successfully enrolled in global registrational study in Australia - Operational presence in Australia positions Serina to advance enrollment in Cohort 1- Company remains on track for first patient dosing in the first quarter of 2026 HUNTSVILLE, AL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing drug candidates enabled by its proprietary POZ Platform™ drug optimization technology, today announced that the first patient has been enrolled in the Company's Phase 1b registrational trial evaluating SER-252 in patients with advanced Parkinson's disease. The Phase 1b registratio

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

EFFECT - Serina Therapeutics, Inc. (0001708599) (Filer)

4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

"Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"  Featuring Serina Therapeutics' CEO - Wednesday, February 4, 2026 Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sectorMeet with Serina's CEO Steven LedgerRegister at New-FDA-Era.TribePublic.com HUNTSVILLE, AL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Serina's CEO, Steven Ledger will present at Tribe Public's Webinar Presentation a